Tapestry reports evidence that TPI 287 works orally, fights tumors

New York, April 3 - Tapestry Pharmaceuticals, Inc. said it presented data on its lead oncology drug candidate 287 that showed it was orally bioavailable in rats and that oral dosing of the drug has antitumor activity in a mouse xenograft model.

The results were presented at the 97th annual meeting of the American Association for Cancer Research in Washington, D.C.

TPI 287, a proprietary third generation taxane, is Tapestry's lead clinical compound. It was designed to overcome multi-drug resistance in solid tumors that have become resistant to taxane therapy.

In preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and has shown inhibition of human tumors in certain animal xenograft models when tested against standard comparative agents.

TPI 287 is in two phase 1 studies in the United States and overseas to determine the safety and pharmacokinetic profile of the compound. A number of phase 2 studies are planned in several of the major tumor types and are projected to begin in this calendar year.

Tapestry is a Boulder, Colo., pharmaceutical company developing cancer treatments.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.